Your browser doesn't support javascript.
loading
Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.
Serra, Lidia; Webber, Chris; Burman, Cindy; Bueti, Patrizia; Gorruso, Maria; Mather, Susan.
Affiliation
  • Serra L; Pfizer Vaccine Emerging Markets and China Medical and Scientific Affairs, Collegeville, PA, USA.
  • Webber C; Pfizer Vaccine Clinical Research and Development, Hurley, UK.
  • Burman C; Pfizer Vaccine Medical Development and Scientific/Clinical Affairs, Collegeville, PA, USA.
  • Bueti P; Pfizer Worldwide Safety, Safety Surveillance and Risk Management, Collegeville, PA, USA.
  • Gorruso M; Pfizer Worldwide Safety, Safety Surveillance and Risk Management, Collegeville, PA, USA.
  • Mather S; Pfizer Worldwide Safety, Safety Surveillance and Risk Management, Collegeville, PA, USA. Electronic address: Susan.Mather@pfizer.com.
Vaccine ; 40(49): 7014-7021, 2022 11 22.
Article in En | MEDLINE | ID: mdl-36283896
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tetanus Toxoid / Meningococcal Vaccines / Meningococcal Infections Type of study: Clinical_trials Limits: Humans Language: En Journal: Vaccine Year: 2022 Document type: Article Affiliation country: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tetanus Toxoid / Meningococcal Vaccines / Meningococcal Infections Type of study: Clinical_trials Limits: Humans Language: En Journal: Vaccine Year: 2022 Document type: Article Affiliation country: Estados Unidos